Skip to main content

Table 3 Incidence of liver events, cardiovascular events, type 2 diabetes mellitus, and non-liver malignancies in patients with NAFLD

From: Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease

Events

Overall

Lean NAFLDa

Non-lean NAFLDb

n/N (%)

1000 person years

n/N (%)

1000 person years

n/N (%)

1000 person years

Liver-related events

11/405 (2.7%)

3.72

4/148 (2.7%)

3.08

7/257 (2.7%)

4.23

 Liver cancer

9/418 (2.2%)

2.96

6/155 (3.9%)

4.49

3/263 (1.1%)

1.76

 Hepatic encephalopathy

6/444 (1.4%)

1.86

3/168 (1.8%)

2.11

3/276 (1.1%)

1.67

 Esophagogastric varices

7/432 (1.6%)

2.22

3/163 (1.8%)

2.16

4/269 (1.1%)

2.26

 Ascites

9/441 (2.0%)

2.80

4/167 (2.4%)

2.82

5/274 (1.8%)

2.78

 Jaundice

3/442 (0.7%)

0.93

0/167 (0.0%)

0.00

3/275 (1.1%)

1.68

Cardiovascular events

36/443 (8.1%)

11.72

15/168 (8.9%)

11.07

21/275 (7.6%)

12.24

Type 2 diabetes mellitus

34/298 (11.4%)

15.43

12/128 (9.4%)

10.95

22/170 (12.9%)

19.88

Non-liver malignancies

26/406 (6.4%)

9.06

12/152 (7.9%)

9.60

14/254 (5.5%)

8.65

  1. n; number of events, N; number of patients free or with the respective event at the time of NAFLD diagnosis
  2. aLean NAFLD, BMI < 25.0 kg/m2, bnon-lean NAFLD, BMI ≥ 25.0 kg/m2